About 151,474 results

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

We present severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) real-time RT-PCR results of all respiratory and faecal samples from patients with coronavirus disease 2019 (COVID-19) at the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China, throughout the course of their illness and obligated quarantine period.

SARS-CoV-2 and Nervous System - Neurological Manifestations in Patients With COVID-19: A Systematic Review

Coronavirus (CoV) is a virus infectious disease with a considerable spectrum of clinical presentations. Symptoms ranged from asymptomatic infection to severe pneumonia that may lead to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and several clinical complications. Neurologic symptoms related to CoV have been described recently in the literature. The relationship between SARS-Co...

COVID-19 and Food Safety: Risk Management and Future Considerations

COVID-19, also known as the “novel coronavirus disease 2019,” is a respiratory illness, and the causative pathogen is officially named as “SARS-CoV-2.” Infections with SARS-CoV-2 have now been amplified to a global pandemic—as of April 3, 2020, nearly 1 018 000 cases have been confirmed in more than 195 countries, including more than 300 000 cases within the United States. Public safety guideli...

Lung ultrasound monitoring in patients with COVID-19 on home isolation

Many patients with COVID-19, the clinical illness caused by SARS-CoV-2 infection, exhibit mild symptoms and do not require hospitalization. Instead, these patients are often referred for 14-days of home isolation as symptoms resolve. Lung ultrasound is well-established as an important means of evaluating lung pathology in patients in the emergency department and in intensive care units. Ultraso...

Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection

Community Prevalence of SARS-CoV-2 Among Patients With Influenzalike Illnesses Presenting to a Los Angeles Medical Center in March 2020

Until recently, diagnostic testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was only available through public health laboratories.1-3 This limited testing was prioritized for persons who had severe illness or identifiable risk factors, such as travel to an area with ongoing transmission. Thus, the incidence of c...

Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause

As part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leading to the voluntary pause of vaccination across all trials to allow an independent committee to review the safety data of a single event of an unexplained illness that occurred in the UK Phase III trial. This is a routine act...

COVID-19: the older adult and the importance of vitamin D sufficiency

In December 2019, in Wuhan, China, the novel coronavirus ‘severe acute respiratory syndrome 2’ (SARS-CoV-2) was discovered as the cause of a pneumonia-like illness and subsequently named coronavirus disease 2019 (COVID-19). COVID-19 spread and is now a global pandemic. With few exceptions, countries in the Northern hemisphere have higher mortality rates from COVID-19. This may be due to an incr...

Impairments in Activities of Daily Living in Parkinson's Disease: Implications for Management

Sep 9th, 2003 - Parkinson's disease (PD) is a neurodegenerative disorder with progressive impairment in motor and cognitive functioning. A review of past research shows that individuals experience not only physical discomfort brought on by the illness, but also considerable psychological distress. Increased dependency on a caregiver due to impairments in activities of daily living (e.g., walking, eating, dress...

The Concept of Prodromal Parkinson’s Disease
Journal of Parkinson's Disease;

Parkinson’s disease (PD) is currently clinically defined by a set of cardinal motor features centred on the presence of bradykinesia and at least one additional motor symptom out of tremor, rigidity or postural instability. However, converging evidence from clinical, neuropathological, and imaging research suggests initiation of PD-specific pathology prior to appearance of these classical motor...

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
NPJ Parkinson's Disease;

Levodopa-induced dyskinesias (LID) negatively impact on the quality of life of patients with Parkinson’s disease (PD). We assessed the risk factors for LID in a cohort of de-novo PD patients enrolled in the Parkinson’s Progression Markers Initiative (PPMI). This retrospective cohort study included all PD patients enrolled in the PPMI cohort. Main outcome was the incidence rate of dyskinesia, de...

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
JAMA Internal Medicine;

Jul 14th, 2020 - Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection began in December 2019 in Wuhan, China, more than 6 million people have developed coronavirus disease 2019 (COVID-19), and more than 350 000 have died.1 Critical illness from COVID-19 in China, Italy, and other countries has strained intensive care unit (ICU) resources and produced a wide spectrum of sh...

Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer

Although the benefit of population-level public facial masking to protect others during the COVID-19 pandemic has received a great deal of attention, we discuss for one of the first times the hypothesis that universal masking reduces the “inoculum” or dose of the virus for the mask-wearer, leading to more mild and asymptomatic infection manifestations. Masks, depending on type, filter out the m...

Acute Respiratory Distress Syndrome: Diagnosis and Management

Acute respiratory distress syndrome (ARDS) is noncardiogenic pulmonary edema that manifests as rapidly progressive dyspnea, tachypnea, and hypoxemia. Diagnostic criteria include onset within one week of a known insult or new or worsening respiratory symptoms, profound hypoxemia, bilateral pulmonary opacities on radiography, and inability to explain respiratory failure by cardiac failure or flui...

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic...

Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease
Clinical Rheumatology; Queiro

Mar 26th, 2019 - High blood pressure (HBP) is a common comorbidity in psoriatic disease. Some studies indicate a higher prevalence of HBP among arthritis patients, in relation to psoriasis alone, within the psoriatic spectrum. Our objective was to study the prevalence of HBP in both types of patients as well as to analyse the factors associated with it.

Impacts of COVID-19 on Liver Cancers: During and after the Pandemic
Liver Cancer; Chan SL

Aug 31st, 2020 - The pandemic of coronavirus disease 2019 (COVID-19) has diverted resources from healthcare services for patients with chronic medical illness such as cancer. COVID-19 also causes organ dysfunction, complicating cancer treatment. In most countries with an outbreak of COVID-19, modifications of cancer management have been adopted to accommodate the crisis and minimize the exposure of cancer patie...

The hallmarks of COVID-19 disease
PLoS Pathogens;

May 21st, 2020 - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that has caused a worldwide pandemic of the human respiratory illness COVID-19, resulting in a severe threat to public health and safety.

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
New England Journal of Medicine; Goldman, JD.

The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has plunged large parts of the world into a protracted medical, social, and economic crisis.1-4 Coronavirus disease 2019 (Covid-19), the respiratory illness caused by SARS-CoV-2 infection, has caused over a quarter million deaths worldwide, including approximately 100,000 in the United States.

Remdesivir for the Treatment of Covid-19 — Final Report
New England Journal of Medicine; Beigel, JH. .

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness designated coronavirus disease 2019, or Covid-19.1 Several therapeutic agents have been evaluated for the treatment of Covid-19, but no antiviral agents have yet been shown to be efficacious.